Hangzhou-based Lynk Pharmaceuticals Co., Ltd announced it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its drug LNK01004 for atopic dermatitis (AD). The drug was previously approved for a clinical trial in mild to moderate plaque psoriasis, with the first patient dosed in a Phase I study in China last month.
Drug Profile
LNK01004 is a novel kinase inhibitor capable of inhibiting multiple cytokine-induced signaling pathways in vitro and in vivo. As a tissue-restricted inhibitor, the drug is designed to prevent safety issues associated with systemic exposure, potentially offering a safer treatment option for patients.
Clinical Trial Progress
The approval for the AD study follows the initiation of a Phase I trial in plaque psoriasis, marking progress in Lynk Pharma’s development pipeline. The company plans to explore LNK01004’s efficacy and safety in treating AD, building on its existing clinical data.-Fineline Info & Tech
